HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Vaporization of prostates of > or =80 mL using a potassium-titanyl-phosphate laser: midterm-results and comparison with prostates of <80 mL.

AbstractOBJECTIVE:
To compare the safety and outcome of potassium-titanyl-phosphate (KTP) Greenlight (Laserscope, AMS, Minnetonka, MN, USA) vaporization for treating benign prostatic hyperplasia (BPH) in prostates of > or =80 vs <80 mL.
PATIENTS AND METHODS:
In all, 204 consecutive patients were enrolled into this prospective study; 31 were excluded from analysis for various reasons, thus 173 (median age 66.8 years; 39 with prostates of > or =80 mL) were evaluated for maximum urinary flow rate (Q(max)), postvoid residual urine (PVR), the International Prostate Symptom Score (IPSS), and quality-of-life (QoL) score. The median follow-up was 11.7 months. Of the 173 men, 26.6% were anaesthesiological high-risk patients and 32.4% took anticoagulants.
RESULTS:
The Q(max) improved in prostates of > or =80 mL from 6.9 mL/s before to 15.3 mL/s immediately after catheter removal, and 23.4 mL/s after 3 months (P < 0.001). The improvement was similar to that in smaller prostates. There were equally effective changes in PVR (P < 0.001). The IPSS decreased from 19.0 before to 7.0, 4.0 and 5.5 at 3, 6 and 12 months after surgery (P < 0.001). Changes did not differ from those in smaller glands. The results were similar for QoL (P < 0.001). During surgery there was no major bleeding and no transurethral resection syndrome. There was acute urinary retention after catheter removal in 10.4% of men; 4.6% developed urinary tract infections, whereas the rate was higher in men with larger prostates (10.3%). The re-operation rate was higher in men with larger prostates, at 23.1% vs 10.4% (P = 0.09). CONCLUSION KTP laser vaporization is a safe and effective procedure for surgically treating BPH. The functional outcome in larger prostates is similar to that in smaller glands, but there was a serious trend to a higher re-operation rate in men with larger prostates.
AuthorsJesco Pfitzenmaier, Christian Gilfrich, Maria Pritsch, Daniela Herrmann, Stephan Buse, Axel Haferkamp, Nenad Djakovic, Sascha Pahernik, Markus Hohenfellner
JournalBJU international (BJU Int) Vol. 102 Issue 3 Pg. 322-7 (Aug 2008) ISSN: 1464-410X [Electronic] England
PMID18422772 (Publication Type: Comparative Study, Journal Article)
Topics
  • Aged
  • Aged, 80 and over
  • Humans
  • Lasers, Solid-State (adverse effects, therapeutic use)
  • Male
  • Middle Aged
  • Organ Size
  • Postoperative Complications (etiology)
  • Prospective Studies
  • Prostate (pathology, surgery)
  • Prostatectomy (methods)
  • Prostatic Hyperplasia (pathology, surgery)
  • Quality of Life
  • Reoperation
  • Risk Factors
  • Treatment Outcome
  • Volatilization

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: